ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Holdings Decreased by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 99.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,827 shares of the specialty pharmaceutical company’s stock after selling 566,516 shares during the period. Pacer Advisors Inc.’s holdings in ANI Pharmaceuticals were worth $101,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Sei Investments Co. lifted its position in shares of ANI Pharmaceuticals by 27.8% in the second quarter. Sei Investments Co. now owns 14,473 shares of the specialty pharmaceutical company’s stock worth $922,000 after purchasing an additional 3,152 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $253,000. AQR Capital Management LLC boosted its stake in shares of ANI Pharmaceuticals by 44.8% during the 2nd quarter. AQR Capital Management LLC now owns 17,527 shares of the specialty pharmaceutical company’s stock valued at $1,116,000 after buying an additional 5,419 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of ANI Pharmaceuticals by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,498 shares of the specialty pharmaceutical company’s stock valued at $605,000 after acquiring an additional 1,211 shares in the last quarter. Finally, Kings Path Partners LLC increased its stake in shares of ANI Pharmaceuticals by 18.9% in the third quarter. Kings Path Partners LLC now owns 19,418 shares of the specialty pharmaceutical company’s stock worth $1,158,000 after acquiring an additional 3,086 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Up 1.2 %

ANI Pharmaceuticals stock opened at $58.59 on Wednesday. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -106.53 and a beta of 0.74. The firm has a fifty day moving average price of $56.61 and a two-hundred day moving average price of $58.48. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the prior year, the company earned $1.05 EPS. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,381 shares of company stock worth $2,441,556 in the last ninety days. 12.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Finally, StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.